Protagonist Therapeutics, Inc.
PTGX
$45.80
-$0.48-1.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 275.19M | 170.85M | 169.95M | 162.11M | -78.96M |
| Total Depreciation and Amortization | 2.90M | 3.19M | 3.37M | 3.30M | 3.31M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 28.68M | 27.60M | 26.03M | 26.13M | 24.92M |
| Change in Net Operating Assets | -122.61M | 28.65M | 32.19M | -254.86M | -19.51M |
| Cash from Operations | 184.15M | 230.29M | 231.54M | -63.32M | -70.24M |
| Capital Expenditure | -1.36M | -1.06M | -693.00K | -841.00K | -609.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -298.13M | -350.98M | -156.20M | -42.17M | -38.65M |
| Cash from Investing | -299.48M | -352.05M | -156.89M | -43.01M | -39.26M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 26.45M | 22.95M | 46.21M | 152.48M | 171.25M |
| Repurchase of Common Stock | -600.00K | -600.00K | -600.00K | -1.27M | -769.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 25.85M | 22.35M | 45.61M | 151.21M | 170.48M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -89.48M | -99.41M | 120.26M | 44.88M | 60.98M |